EnVivo Pharmaceuticals has changed its name to FORUM Pharmaceuticals. The new name better reflects the company’s strong position as a late-stage, purpose-built organization that is focused on conquering brain diseases such as schizophrenia and Alzheimer’s disease. It is not associated with any changes in organizational structure or the company’s investor base.
“The name FORUM captures our commitment to perseverance and innovation, and highlights our bold approach to bringing new therapies to help people with serious brain diseases overcome their everyday symptoms,” said Deborah Dunsire, M.D., president and CEO of FORUM. “Historically, a forum is a place where people come together to debate and share ideas. As FORUM Pharmaceuticals, we are combining that spirit of collaboration with a singular focus on brain disease, to find and develop new medicines that improve patients’ abilities to function—striving to help them maintain critical connections, live more fully, and ultimately, to change the course of their disease.”
FORUM has a robust and diverse pipeline focused on innovative solutions for neuropsychiatric conditions. The company’s lead compound, encenicline hydrochloride (EVP-6124), is a novel alpha-7 (α7) potentiator currently being evaluated in separate ongoing phase III COGNITIV clinical trial programs. The first trial is focused on patients with cognitive impairment in schizophrenia (COGNITIV CIAS). The second is focused on improving cognition in patients with Alzheimer’s disease (COGNITIV AD).